Drug Type Small molecule drug |
Synonyms next-generation derivatives of the sabizabulin scaffold |
Target |
Mechanism TUB modulators(TUB bipartite transcription factor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | US | 02 May 2024 | |
Triple Negative Breast Cancer | Preclinical | US | 02 May 2024 |